ENGN Share Price Performance
US$8.53
0.87 (11.36%)
Price US$8.53
Share Pricen/a
enGene Holdings Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ENGN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
enGene Holdings Inc. Key Details
About ENGN
- Founded
- n/a
- Employees
- 57
- CEO
- WebsiteView website
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
